Finally, a New FDA Approved Treatment for Hives
Long awaited good news for hive sufferers! The FDA has approved Xolair (omalizumab) for the treatment of chronic hives (lasting longer than 6 weeks) that are not controlled with antihistamines. This is wonderful news for many people suffering from the debilitating effects of intractable hives. Prior to Xolair, treatment for refractory hives were limited to immunosuppressant medications. Xolair is not first line therapy for hives and not everyone with hives will be a candidate for Xolair. However, it is expected that the FDA’s approval should improve insurance coverage and patient access for those who require it.